Targovax

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

MoneyHero

MCap

USD60m

Last close

USD2.35

▲ 0.55 (30.56%)

MGI – Media and Games Invest

MCap

EUR235m

Last close

EUR1.50

▲ 0.35 (30.21%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Targovax. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
Update

17.09.20

Targovax — Growing list of collaborations and more data in H2

Healthcare |
Update

22.06.20

Targovax — Confirmatory 12-month mesothelioma update

Healthcare |
Update

28.05.20

Targovax — ONCOS-102 plus durvalumab trial in spotlight

Healthcare |
Update

23.03.20

Targovax — More data in 2020 from both clinical trials

Visit Website

Sector

Healthcare

Financials

Edison Investment Research is terminating coverage on Targovax. Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Update

Healthcare

16.03.18

Targovax — Key catalysts in 2018

Initiation

Healthcare

08.11.17

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

Targovax (NO: TRVX)

Latest Insights

Targovax — Growing list of collaborations and more data in H2

Targovax — Confirmatory 12-month mesothelioma update

Targovax — ONCOS-102 plus durvalumab trial in spotlight

Targovax — More data in 2020 from both clinical trials

Sector

Financials

Targovax — Key catalysts in 2018

Targovax — Priming immune response in anticancer combos